Results 11 to 20 of about 6,789 (241)

Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis. [PDF]

Aliment Pharmacol Ther
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Abbas N, Smith R, Lytvyak E, Scaravaglio M, Halliday N, Almahroos A, Eden N, Lloyd-Madden D, Sharma S, Ferguson J, Dyson JK, Thorburn D, Jones D, Montano-Loza AJ, Carbone M, Invernizzi P, Mells G, Culver EL, Trivedi PJ.   +18 more
europepmc   +4 more sources

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases [PDF]

Frontiers in Medicine, 2020
In the past ten years, our understanding of the importance of bile acids has expanded from fat absorption and glucose/lipid/energy homeostasis into potential therapeutic targets for amelioration of chronic cholestatic liver diseases.
Vik Meadows, Vik Meadows, Lindsey Kennedy, Debjyoti Kundu, Gianfranco Alpini, Gianfranco Alpini, Heather Francis, Heather Francis   +7 more
doaj   +3 more sources

Obeticholic acid prevents cyclophosphamide-induced placental injury via SIRT1 and TLR4/NF-κB pathways [PDF]

BMC Pharmacology and Toxicology
Background The aim of the current study is to identify the possible protective effect of obeticholic acid (OCA) on placental injury caused by cyclophosphamide (CP). OCA was administered in the presence and absence of CP.
Walaa Yehia Abdelzaher, Hanaa Mohamed Khalaf, Sara M. Ahmed, Mina Ezzat Attya, Abdelaleem Abdelnour Mohamed, Asmaa Mohamed Mahmoud Ali, Shereen S. Gaber, Ahmed K. A. Abdel-Hakeem, Enas Mostafa Mohammed, Marwa Hassan   +9 more
doaj   +2 more sources

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease [PDF]

Biology Direct, 2023
The response rate to obeticholic acid (OCA), a potential therapeutic agent for non-alcoholic fatty liver disease, is limited. This study demonstrated that upregulation of the alternative bile acid synthesis pathway increases the OCA treatment response ...
Seung Min Lee, Dae Won Jun, Eileen Laurel Yoon, Ju Hee Oh, Yoon Jin Roh, Eun Jeoung Lee, Ji-Hee Shin, Young-Do Nam, Hyun Sung Kim   +8 more
doaj   +2 more sources

Effects of Obeticholic Acid Treatment on Primary Human Hepatocytes in a Novel Tri-Culture Model System [PDF]

Cells
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing health concern worldwide. Human cell-based in vitro culture models that retain disease-relevant phenotypic pathways and responses to assess the efficacy and liability of new ...
Justin J. Odanga, Sharon M. Anderson, Edward L. LeCluyse, Sharon C. Presnell, Jingsong Chen, Jessica R. Weaver   +5 more
doaj   +2 more sources

Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis [PDF]

Liver Research, 2022
Background and aims: Several bile acids-based monotherapies have been developed for non-alcoholic steatohepatitis (NASH) treatment but clinical trial findings suggest that they do not satisfactorily improve NASH and liver fibrosis in many patients ...
David J. Matye, Xuan Qin, Mohammad Nazmul Hasan, Lijie Gu, Yung Dai Clayton, Feng Li, Tiangang Li   +6 more
doaj   +2 more sources

Protective Effect of Obeticholic Acid on Sepsis-Induced Liver Dysfunction via Regulating Bile Acid Homeostasis [PDF]

Pharmaceuticals
Background/Objectives: Abnormal bile acid (BA) pool may play an important role in inducing liver damage in sepsis. Farnesoid X receptor (FXR) is a main negative feedback regulator of BA metabolism.
Jiahui Wang, Li Ma, Yuan An, Yan Ge, Dan Xu, Enqiang Mao   +5 more
doaj   +2 more sources

Obeticholic acid and 5β-cholanic acid 3 exhibit anti-tumor effects on liver cancer through CXCL16/CXCR6 pathway [PDF]

Frontiers in Immunology, 2022
Hepatocellular carcinoma (HCC) is the most common type of liver malignancy with a high incidence and mortality rate. Previous in vitro and in vivo studies have confirmed that liver sinusoidal endothelial cells (LSEC) secrete CXCL16, which acts as a ...
Haoxian Gou, Haoxian Gou, Shenglu Liu, Linxin Liu, Ming Luo, Shu Qin, Kai He, Kai He, Xiaoli Yang, Xiaoli Yang   +9 more
doaj   +2 more sources

Bioequivalence and Pharmacokinetic Profiles of Generic and Branded Obeticholic Acid in Healthy Chinese Subjects Under Fasting and Fed Conditions

Drug Design, Development and Therapy, 2021
Meng-Na Wang,1,* Hai-Tao Yu,2,* Ya-Qian Li,1 Yun Zeng,1 Shuang Yang,3 Guo-Ping Yang,1,3– 6 Qi Pei,6 Jie Huang1,3 1Center for Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, People’s ...
Wang MN, Yu HT, Li YQ, Zeng Y, Yang S, Yang GP, Pei Q, Huang J   +7 more
doaj   +3 more sources

Obeticholic acid: expanding the therapeutic landscape of NASH

Annals of Hepatology, 2015
Currently treatment options for Non-Alcoholic Steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease (NAFLD) and one of the commonest causes of cirrhosis worldwide, are mainly limited to promotion of life style changes in diet and exercise habits as well as to control of comorbidities such as type 2 diabetes mellitus and ...
Marco Arrese, Daniel Cabrera, Francisco Barrera   +2 more
doaj   +3 more sources